Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics       

NEKTAR THERAPEUTICS
My previous session
Most popular
  Report  
End-of-day quote. End-of-day quote  - 07/20
48.73 USD   -0.71%
09/14S&P 500 MOVERS : Ni, adbe
AQ
08/16S&P 500 MOVERS : Nktr, wmt
AQ
08/08NEKTAR : 2Q Earnings Snapshot
AQ
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Financials (USD)
Sales 2018 1 181 M
EBIT 2018 692 M
Net income 2018 669 M
Finance 2018 469 M
Yield 2018 -
Sales 2019 296 M
EBIT 2019 -233 M
Net income 2019 -251 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 14,94
P/E ratio 2019
Capi. / Sales2018 7,88x
Capi. / Sales2019 33,1x
Capitalization 9 777 M
More Financials
Company
Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms.It operates through the United States and Europe geogrpahical segments.The company was founded in 1990 and is... 
Sector
Biotechnology & Medical Research
Calendar
10/22 | 12:45pmPresentation
More about the company
Surperformance© ratings of Nektar Therapeutics
Trading Rating : Investor Rating :
More Ratings
Latest news on NEKTAR THERAPEUTICS
09/14S&P 500 MOVERS : Ni, adbe
AQ
09/13NEKTAR THERAPEUTICS : "Oligomer-Phenothiazine Conjugates" in Patent Application ..
AQ
09/05NEKTAR THERAPEUTICS : Today's Research Reports on Trending Tickers: Cronos Group..
AC
08/16S&P 500 MOVERS : Nktr, wmt
AQ
08/10NEKTAR THERAPEUTICS : U.S. Patents Awarded to Inventors in Alabama (Aug. 10)
AQ
08/09NEKTAR THERAPEUTICS : New Findings from Nektar Therapeutics in the Area of Breas..
AQ
08/09NEKTAR THERAPEUTICS : Patent Issued for Heterobifunctional Poly(Ethylene Glycol)..
AQ
08/09NEKTAR THERAPEUTICS : Announces New Drug Application for NKTR-181 Accepted for R..
AQ
08/09TODAY'S RESEARCH REPORTS ON TRENDING : Nektar Therapeutics and Sangamo Therapeut..
AC
08/09NEKTAR THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
07/12ROUNDS REPORT : Aveo Catches A Big Payday With NHSScotland Approval Of Tivozanib 
07/06S&P 1500 Misfit Stocks 
07/06Biogen leads biotechs into positive territory 
07/05ROUNDS REPORT : Adamis Rallied Due To A Commercialization Partnership 
06/29ROUNDS REPORT : Nektar Positioned As A Stellar Buying Opportunity Amid Strong Ma.. 
Chart NEKTAR THERAPEUTICS
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 89,4 $
Spread / Average Target 58%
EPS Revisions
Managers
NameTitle
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
John Nicholson Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
Stephen K. Doberstein Chief Research & Development Officer, Senior R&D
Sector and Competitors
1st jan.Capitalization (M$)
NEKTAR THERAPEUTICS-18.40%9 777
CELLTRION, INC.--.--%33 722
IQVIA HOLDINGS INC27.92%25 338
LONZA GROUP21.88%24 487
INCYTE CORPORATION-28.39%14 247
SEATTLE GENETICS, INC.45.25%12 094